Achieving the Sustained Virologic Response With a Short-Course Treatment of Sofosbuvir/Velpatasvir.
| Autor: | Abi-Saleh SP; Internal Medicine, University of Connecticut School of Medicine, Farmington, USA., Ghazal F; Internal Medicine, University of Connecticut School of Medicine, Farmington, USA., Urtasun Sotil E; Gastroenterology and Hepatology, Hartford Hospital, Hartford, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Apr 04; Vol. 15 (4), pp. e37126. Date of Electronic Publication: 2023 Apr 04 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.37126 |
| Abstrakt: | Hepatitis C, a single-stranded RNA virus officially discovered in 1989, is one of the most known viruses of the Flaviviridae family. Direct-acting antiviral drugs helped revolutionize the management of hepatitis C infection by guaranteeing higher cure rates. The medical field has strived to optimize the management of this disease, with recent reports proposing a shorter treatment duration to achieve the sustained virologic response (SVR). We present a case of a patient diagnosed with hepatitis C decompensated liver cirrhosis who achieved the SVR after only two weeks of treatment with sofosbuvir/velpatasvir, suggesting that short-term therapy might be beneficial for these patients. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Abi-Saleh et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|